# Cardinal Health Inc: Form 10-Q for the period ended Mar 31, 2023

- Company: [Cardinal Health Inc](/companies/cah.md) (CIK 721371)
- Form: 10-Q
- Filed: 2023-05-04
- Accepted by EDGAR: May 4, 2023, 20:25 ET
- Period: 2023-03-31
- Accession: 0001628280-23-015775
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/721371/000162828023015775/cah-20230331.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/721371/000162828023015775/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2023-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2023-01-01 to 2023-03-31 | $50.49bn | us-gaap:Revenues |
| Revenue | 9 months, 2022-07-01 to 2023-03-31 | $151.56bn | us-gaap:Revenues |
| Cost of revenue | 3 months, 2023-01-01 to 2023-03-31 | $48.70bn | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months, 2022-07-01 to 2023-03-31 | $146.50bn | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2023-01-01 to 2023-03-31 | $1.78bn | us-gaap:GrossProfit |
| Gross profit | 9 months, 2022-07-01 to 2023-03-31 | $5.06bn | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months, 2023-01-01 to 2023-03-31 | $1.18bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2022-07-01 to 2023-03-31 | $3.57bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2023-01-01 to 2023-03-31 | $572.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2022-07-01 to 2023-03-31 | $590.0m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2023-01-01 to 2023-03-31 | $28.0m | us-gaap:InterestExpense |
| Interest expense | 9 months, 2022-07-01 to 2023-03-31 | $78.0m | us-gaap:InterestExpense |
| Income tax | 3 months, 2023-01-01 to 2023-03-31 | $197.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2022-07-01 to 2023-03-31 | $189.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2023-01-01 to 2023-03-31 | $345.0m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2022-07-01 to 2023-03-31 | $325.0m | us-gaap:NetIncomeLoss |
| Diluted shares (weighted) | 3 months, 2023-01-01 to 2023-03-31 | 258,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2022-07-01 to 2023-03-31 | 264,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2022-07-01 to 2023-03-31 | $1.98bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2022-07-01 to 2023-03-31 | $264.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 9 months, 2022-07-01 to 2023-03-31 | $399.0m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 9 months, 2022-07-01 to 2023-03-31 | $1.50bn | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2023-03-31 | $3.99bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2023-03-31 | $33.50bn | us-gaap:AssetsCurrent |
| Total assets | at 2023-03-31 | $43.38bn | us-gaap:Assets |
| Current liabilities | at 2023-03-31 | $32.50bn | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | at 2023-03-31 | −$2.22bn | us-gaap:StockholdersEquity |

## Sections

No standard item headings were found in this filing’s main document, so no sections were extracted. Read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/721371/000162828023015775/cah-20230331.htm

Filed May 4, 2023.
Source: SEC EDGAR, the filing index for accession 0001628280-23-015775. Last ingested by Listed: Oct 24, 2026, 14:55 ET. No prices; not investment advice.